MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)
October 21, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
September 02, 2021 23:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
September 01, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
August 30, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Reports Second Quarter 2021 Financial Results and Business Update
August 12, 2021 19:00 ET
|
MediciNova, Inc.
Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease under partnership with BARDA Positive Phase 2 results in alcohol use disorder published in...
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease
July 06, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
June 29, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
June 28, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal
June 21, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova to Participate in Maxim Group LLC Fireside Chat
June 14, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...